Evangeline Wassmer

Evangeline Wassmer

Auto-generated profile, based on publicly available information

Evangeline Wassmer

Department of Neurology Birmingham Women's and Children's NHS Foundation Trust Birmingham UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
OAOmar A. Abdel-Mannan
Omar A. Abdel-Mannan
CMCeleste Manchoon
Celeste Manchoon
TRThomas Rossor
Thomas Rossor
JSJustine-Clair Southin
Justine-Clair Southin
CTCarmen Tur
Carmen Tur
YHYael Hacohen
Yael Hacohen
Objectives To compare the real-world effectiveness of newer disease-modifying therapies (DMTs) vs injectables in children with relapsing-remitting multiple sclerosis (RRMS). Methods In this retrospective, multicenter study, from the UK Childhood Inflammatory Demyelination Network, we identified children with RRMS receiving DMTs from January 2012 to December 2018. Clinical and paraclinical data were retrieved from the medical records. Annualized relapse rates (ARRs) before and on treatment, time to relapse, time to new MRI lesions, and change in Expanded Disability Status Scale (EDSS) score were calculated. Results Of 103 children treated with DMTs, followed up for 3.8 years, relapses on treatment were recorded in 53/89 (59.5%) on injectables vs 8/54 (15%) on newer DMTs. The ARR was reduced from 1.9 to 1.1 on injectables (p < 0.001) vs 1.6 to 0.3 on newer DMTs (p = 0.002). New MRI lesions occurred in 77/89 (86.5%) of patients on injectables vs 26/54 (47%) on newer DMTs (p = 0.0001). Children on newer DMTs showed longer time to relapse, time to switch treatment, and time to new radiologic activity than patients on injectables (log-rank p < 0.01). After adjustment for potential confounders, multivariable analysis showed that injectables were associated with 12-fold increased risk of clinical relapse (adjusted hazard ratio [HR] = 12.12, 95% CI = 1.64–89.87, p = 0.015) and a 2-fold increased risk of new radiologic activity (adjusted HR = 2.78, 95% CI = 1.08–7.13, p = 0.034) compared with newer DMTs. At 2 years from treatment initiation, 38/103 (37%) patients had MRI activity in the absence of clinical relapses. The EDSS score did not change during the follow-up, and only 2 patients had cognitive impairment. Conclusion Newer DMTs were associated with a lower risk of clinical and radiologic relapses in patients compared with injectables. Our study adds weight to the argument for an imminent shift in practice toward the use of newer, more efficacious DMTs in the first instance. Classification of Evidence This study provides Class IV evidence that newer DMTs (oral or infusions) are superior to injectables (interferon beta/glatiramer acetate) in reducing both clinical relapses and radiologic activity in children with RRMS.

3 August 2023 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ASAlba Sanchis-Juan
Alba Sanchis-Juan
KMKaryn Megy
Karyn Megy
JSJonathan Stephens
Jonathan Stephens
CRCamila Armirola Ricaurte
Camila Armirola Ricaurte
EDEleanor Dewhurst
Eleanor Dewhurst
KCKeren Carss
Keren Carss

7 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
PGPhilipp Goebl
Philipp Goebl
JWJed Wingrove
Jed Wingrove
OAOmar Abdelmannan
Omar Abdelmannan
BVBarbara Brito Vega
Barbara Brito Vega
JSJonathan Stutters
Jonathan Stutters
AEArman Eshaghi
Arman Eshaghi
Magnetic resonance imaging (MRI) biomarkers are vital for multiple sclerosis (MS) clinical research and trials but quantifying them requires multi-contrast protocols and limits the use of abundant single-contrast hospital archives. We developed MindGlide, a deep learning model to extract brain region and white matter lesion volumes from any single MRI contrast. We trained MindGlide on 4247 brain MRI scans from 2934 MS patients across 592 scanners, and externally validated it using 14,952 scans from 1,001 patients in two clinical trials (primary-progressive MS and secondary-progressive MS trials) and a routine-care MS dataset. The model outperformed two state-of-the-art models when tested against expert-labelled lesion volumes. In clinical trials, MindGlide detected treatment effects on T2-lesion accrual and cortical and deep grey matter volume loss. In routine-care data, T2-lesion volume increased with moderate-efficacy treatment but remained stable with high-efficacy treatment. MindGlide uniquely enables quantitative analysis of archival single-contrast MRIs, unlocking insights from untapped hospital datasets.

8 June 2022 in Clinical Genetics
Verified
Journal Article
Open access
MCMaria B. Christensen
Maria B. Christensen
ALAmanda M Levy
Amanda M Levy
NMNazanin A. Mohammadi
Nazanin A. Mohammadi
MNMarcello Niceta
Marcello Niceta
RKRauan Kaiyrzhanov
Rauan Kaiyrzhanov
Zeynep TümerZeynep Tümer
Zeynep Tümer
Biallelic variants of the gene encoding for the zinc‐finger protein 142 (ZNF142) have recently been associated with intellectual disability (ID), speech impairment, seizures, and movement disorders in nine individuals from five families. In this study, we obtained phenotype and genotype information of 26 further individuals from 16 families. Among the 27 different ZNF142 variants identified in the total of 35 individuals only four were missense. Missense variants may give a milder phenotype by changing the local structure of ZF motifs as suggested by protein modeling; but this correlation should be validated in larger cohorts and pathogenicity of the missense variants should be investigated with functional studies. Clinical features of the 35 individuals suggest that biallelic ZNF142 variants lead to a syndromic neurodevelopmental disorder with mild to moderate ID, varying degrees of delay in language and gross motor development, early onset seizures, hypotonia, behavioral features, movement disorders, and facial dysmorphism. The differences in symptom frequencies observed in the unpublished individuals compared to those of published, and recognition of previously underemphasized facial features are likely to be due to the small sizes of the previous cohorts, which underlines the importance of larger cohorts for the phenotype descriptions of rare genetic disorders.

24 October 2021 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
OAOmar Abdel‐Mannan
Omar Abdel‐Mannan
MAMichael Absoud
Michael Absoud
CBChristina Benetou
Christina Benetou
HHHelga Hickson
Helga Hickson
CHCheryl Hemingway
Cheryl Hemingway
TNThe Uk Childhood Neuroinflammatory Disorders Network
The Uk Childhood Neuroinflammatory Disorders Network
Aim: To describe a 10‐year follow‐up of children (<16y) with acquired demyelinating syndromes (ADS) from a UK‐wide prospective surveillance study.Method: Diagnoses were retrieved from the patients' records via the patients' paediatric or adult neurologist using a questionnaire. Demyelinating phenotypes at follow‐up were classified by an expert review panel.Results: Twenty‐four out of 125 (19.2%) children (64 males, 61 females; median age 10y, range 1y 4mo–15y 11mo), identified in the original study, were diagnosed with multiple sclerosis (incidence of 2.04/million children/year); 23 of 24 fulfilled 2017 McDonald criteria at onset. Aquaporin‐4‐antibody neuromyelitis optica spectrum disorders were diagnosed in three (2.4%, 0.26/million children/year), and relapsing myelin oligodendrocyte glycoprotein antibody‐associated disease in five (4%, 0.43/million children/year). Three out of 125 seronegative patients relapsed and 85 of 125 (68%) remained monophasic over 10 years. Five of 125 patients (4%) originally diagnosed with ADS were reclassified during follow‐up: three children diagnosed initially with acute disseminated encephalomyelitis were subsequently diagnosed with acute necrotising encephalopathy (RAN‐binding protein 2 mutation), primary haemophagocytic lymphohistiocytosis (Munc 13‐4gene inversion), and anti‐N‐methyl‐d‐aspartate receptor encephalitis. One child initially diagnosed with optic neuritis was later diagnosed with vitamin B12 deficiency, and one presenting with transverse myelitis was subsequently diagnosed with Sjögren syndrome.Interpretation: The majority of ADS presentations in children are monophasic, even at 10‐year follow‐up. Given the implications for treatment strategies, multiple sclerosis and central nervous system autoantibody mimics warrant extensive investigation.

8 April 2026 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RRRocio Rius
Rocio Rius
ABAlexander J. M. Blakes
Alexander J. M. Blakes
YCYuyang Chen
Yuyang Chen
JJJoachim De Jonghe
Joachim De Jonghe
FLFrançois Lecoquierre
François Lecoquierre
NWNicola Whiffin
Nicola Whiffin
Genetic variants in RNU4-2 , which is transcribed into the U4 small nuclear RNA component of the major spliceosome, were recently shown to cause ReNU syndrome, a prevalent dominant neurodevelopmental disorder (NDD). These variants almost exclusively arise de novo and cluster within 18 nucleotides of RNU4-2 . Here we describe a new recessive NDD associated with homozygous and compound heterozygous variants in RNU4-2 . We identify 38 individuals with biallelic variants outside the 18-nucleotide ReNU syndrome region that cluster within other functionally important elements of U4: Stem II, the k-turn and the Sm protein binding site. We characterize the clinical phenotype in 31 individuals, demonstrating that the recessive disorder is clinically distinct from ReNU syndrome and is associated with distinctive white matter abnormalities, including enlarged perivascular spaces. Finally, we find reduced RNU4-2 transcript levels in individuals with the recessive disorder, suggesting a loss-of-function disease mechanism that is distinct from the mechanism underlying ReNU syndrome. Together, these findings expand the genotypic and phenotypic spectrum of RNU4-2 -associated NDDs.